Alpha Cognition reported 3Q26 net product revenue of $7.8M, up 30% q/q and more than 230% y/y, supported by continued growth in ZUNVEYL prescriptions and expanding adoption across long-term care facilities. Bottles dispensed increased 31% sequentially to approximately 10,900, while cumulative prescribers reached 2,410, exceeding the Company’s original FY26 target ahead of schedule. Prescriber productivity and repeat prescriptions also improved, supporting continued commercial momentum despite limited changes in formulary coverage. Operating losses narrowed to $6.4M from $7.1M in 2Q26 as revenue growth outpaced operating expenses. Management reiterated FY26 operating expense guidance of $50M–$54M and continues to target operating profitability in 2027. Looking ahead, broader payer access, continued prescriber adoption, and emerging real-world evidence from the CONVERGE and BEACON programs could support further ZUNVEYL commercialization, while the pace of prescription growth and operating leverage remain important considerations.